Clinical pharmacist review
Every fill reviewed by a real PharmD against the patient's full regimen, comorbidities, and plan benefit. Not a fulfillment script.
QuantifyRx is the URAC-accredited pharmacy arm of Quantify Specialty Care (QSC). We dispense, yes — but the dispense is the start of the work, not the end of it. With QSC behind every fill, we verify the therapy is the right one for the patient's actual condition and physiology. We send registered dietitians when food is fighting the drug. We send real nurses for real clinical interventions in the home — not a delivery-confirmation phone tree. We loop in behavioral health when staying on therapy is the hardest part. We don't just hand out medication; we make sure the medication actually improves the patient's health.
Where most specialty pharmacies are owned by PBMs, retail chains, or wholesalers, QuantifyRx is owned by a clinical organization whose only customer is the patient and the plan that pays for the care. That changes every incentive. We were founded by clinicians who watched too many patients on high-cost specialty therapies fall through the cracks of dispense-and-ship workflows — missed refills, temperature excursions, anaphylaxis events without a clinician at the other end of the phone, prior auths that died in someone's fax queue, side effects nobody noticed because no one was looking. QuantifyRx exists because that is not acceptable when the drug costs $200,000 a year and the patient's life depends on getting it right.
Real nursing interventions
QSC RNs come to the home for first-fill, infusion supervision, anaphylaxis preparedness, and any clinical event. Not a tech, not a vendor.
Registered dietitian
For therapies where food — protein, dairy, leafy greens, alcohol, grapefruit — changes how the drug works, a dietitian is on the care plan from day one.
Behavioral health support
For patients struggling to stay on high-cost therapy — injection anxiety, depression, adherence fatigue — behavioral health is part of the team, not a referral.
URAC-accredited pharmacy
Accredited specialty pharmacy operations under URAC — the gold standard for specialty pharmacy accreditation. Accreditation ID MSP010001. Verify on URAC AccreditNet →
NHIA member
Active member of the National Home Infusion Association — the standard-setter for home and alternate-site infusion practice in the United States.
NCPA member
Active member of the National Community Pharmacists Association — the trade group representing more than 19,400 independent community pharmacies advocating for patient access and community-rooted pharmacy practice.
Anaphylaxis-trained, REMS-Plus operations
Anaphylaxis-trained RNs, standardized epinephrine kits, documented patient and caregiver education. The operating standard for every high-risk therapy — not a per-drug retrofit.
Meet the pharmacist leading QuantifyRx
Carl Black, PharmD
Chief Pharmacy Officer · QuantifyRx
We built QuantifyRx out together because Carl got tired of watching patients hit walls he knew shouldn't exist. Red tape. Carve-out gymnastics. Pharmacies that handed members off to call centers, prior auths that died in fax queues, prescribers who never heard back, and patients who gave up on therapy because the system was too exhausting to navigate when they were already sick.
Together we set out to build something that actually changed lives — not just dispensed drugs. With QSC behind it, QuantifyRx doesn't stop at the bottle leaving the shelf. We confirm the therapy is the right one for the patient in front of us. We send a registered dietitian when food and the drug are working against each other. We send a real nurse to the home for real clinical interventions — not a delivery-confirmation phone tree. We loop in behavioral health when a patient is struggling to stay on therapy. A pharmacy with a purpose: get the right medication to the right patient, with the clinical wrap-around to make sure they actually get better. That is the entire job. Everything else is overhead.
As Chief Pharmacy Officer, Carl oversees all dispensing, REMS-Plus operations, clinical pharmacy practice, and the cold-chain workflow at our Fort Lauderdale facility. He is the pharmacist of record for the URAC accreditation and the named operational owner for every manufacturer relationship.
“Dispensing the drug is the easy part. Making sure it's the right drug, that the patient can take it, that the food they eat doesn't fight it, and that a nurse shows up when something changes — that's the part most of specialty pharmacy walked away from. We didn't.”
Liane Parker, RN, CPHM
Co-Founder · Chief Clinical Operating Officer, Quantify Specialty Care
Operations & Partner Integration for QuantifyRx. Liane runs the clinical operation that wraps every dispense — RN home visits, 24/7 Command Center, plan-side reporting, and partner integrations.
Alberto Montero, MD
Chief Medical Officer, Quantify Specialty Care · Chair, Quality Medical Oversight Committee
Board-certified oncologist who chairs the multi-specialty committee that reviews QuantifyRx treatment plans, prior-auth decisions, and protocol appropriateness. The medical guardrail that makes sure the dispense in front of us is actually the right care.
The full QSC clinical leadership team is on the Quantify Specialty Care site →
Quality Medical Oversight Committee
A multi-specialty review board sits between every prescription and every patient.
Most specialty pharmacies dispense whatever the prescription says. We don't. Before high-cost or high-risk therapy goes out the door, the Quantify Quality Medical Oversight Committee — a standing panel of board-certified physicians across oncology, cardiology, endocrinology, infectious disease, and internal medicine, paired with senior clinical nurses — reviews the case for medical appropriateness, evidence-based protocol fit, and patient safety. We don't just check whether the drug can be billed. We check whether it's the right treatment.
What the committee reviews
- Complex oncology, autoimmune, rare-disease, and high-cost specialty cases
- Treatment protocols proposed by the prescribing physician — against current evidence and patient-specific factors
- Prior authorization decisions where the plan or PBM denial may be clinically wrong
- Drug-drug interactions, contraindications, and physiologic risk profiles
- Cases where a less invasive, equally effective therapy may be the better choice
Who sits on the committee
- Alberto Montero, MD — Chair. Board-certified medical oncology.
- Specialty physician advisors across cardiology, endocrinology, infectious disease, internal medicine, and pediatrics
- Senior clinical RNs with infusion, oncology, and complex-care experience
- Carl Black, PharmD — Chief Pharmacy Officer, voting member on dispensing and REMS questions
- Liane Parker, RN, CPHM — Operations lead, ensures committee decisions reach the bedside
A recent committee review
A patient was scheduled to start systemic chemotherapy. Dr. Montero reviewed the case, pulled the pathology, the staging, and the recent imaging together, and identified that a less invasive, evidence-supported therapy was both safer for this patient's comorbidity profile and clinically superior given the actual tumor characteristics. The treatment plan was changed before the first cycle started. The patient avoided unnecessary toxicity, the plan avoided the cost of a wrong-protocol regimen, and the outcome was better — not because we dispensed faster, but because a physician actually looked at the chart.
This is the difference between a pharmacy that ships and a pharmacy that practices.